Be interesting to see how market reacts to news/no news on Tuesday. And then there is the uncertainty of the proxy fight and injunction. If there is a dip, I will be adding; bladder data at ASCO was great, and breast cancer indication has been fast-tracked. Actually, this stock is cheap, in one year, it will be double or triple easy.